NeuroBo closes $32.3M financing and licenses NASH/obesity drugs from Dong-A

On November 4, 2022, the Company filed the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “ Series A Certificate of Designations ”) and the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the “ Series B Certificate of Designations ,” and together with the Series A Certificate of Designations, the “ Certificate of Designations ”) with the Secretary of State of the State of Delaware.

On November 4, 2022, NeuroBo Pharmaceuticals, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with Ladenburg Thalmann & Co. Inc. (the “ Underwriter ”), pursuant to which the Company issued and sold, in an underwritten public offering by the Company (the “ Public Offering ”), (a) 2,397,003 Class A Units (the “ Class A Units ”), with each Class A Unit consisting of (i) one share of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), (ii) one warrant to purchase one share of Common Stock exercisable following approval of the Company’s stockholders (each, a “ Series A Warrant ”) and (iii) one warrant to purchase one share of Common Stock exercisable following approval of the Company’s stockholders (each, a “ Series B Warrant ,” and together with the Class A Series A Warrants, the “ Warrants ”), with each Class A Unit offered to the public at an offering price of $3.00 per Class A Unit and (b) 2,602,997 Class B Units

On November 8, 2022, the Company also entered into a warrant agency agreement with the Company’s transfer agent, American Stock Transfer & Trust Company LLC, who will act as warrant agent for the Company, setting forth the terms and conditions of the Warrants sold in the Public Offering (the “ Warrant Agency Agreement ”).